Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
UTUnited Therapeutics Corporation logo

United Therapeutics Corporation (UTHR)

NASDAQ Global Select · Currency in USD
$587.50 ▲ +2.71 (+0.46%)
At close: Oct 23, 4:00 PM ET. Market closed.
$595.00 ▲ +7.50 (+1.28%)
After hours: Oct 23, 7:45 PM ET

Summary

Previous Close
$584.79
Open
$584.92
Day's Range
$576.24 – $590.98
52 Week Range
$409.07 – $609.35
Volume
621,269
Avg. Volume
657,388
Market Cap
$25.20B
Beta (5Y Monthly)
0.56
PE Ratio (TTM)
19.43
EPS (TTM)
$30.77
Earnings Date
Nov 4, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$651.63

Profile: United Therapeutics Corporation

Sector
Healthcare
Industry
Biotechnology
Full-time employees
1,400
CEO
Martine A. Rothblatt

United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity.

Earnings

Next report: Wed, Nov 4, 2026
EPS estimate $6.02 · Revenue est. $781.56M
DateEst.Actual
Aug 5, 2026$6.86$7.27Beat
May 6, 2026$7.00$5.82Miss
Feb 25, 2026$7.13$7.70Beat
Oct 29, 2025$6.89$7.16Beat
Jul 30, 2025$7.29$6.41Miss
Apr 30, 2025$6.29$6.63Beat

Analyst view

Consensus price target
$651.63 ▲ +10.9%
Range $368.00 – $735.00
Rating: Buy
Buy 58% · Hold 39% · Sell 3%

Get free alerts on UTHR and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.